146 related articles for article (PubMed ID: 8995515)
1. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ
Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of amifostine and its metabolites in patients.
Korst AE; Eeltink CM; Vermorken JB; van der Vijgh WJ
Eur J Cancer; 1997 Aug; 33(9):1425-9. PubMed ID: 9337685
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic profile of amifostine.
Shaw LM; Bonner H; Lieberman R
Semin Oncol; 1996 Aug; 23(4 Suppl 8):18-22. PubMed ID: 8783662
[TBL] [Abstract][Full Text] [Related]
4. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
[TBL] [Abstract][Full Text] [Related]
5. High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma.
Korst AE; Vermorken JB; van der Vijgh WJ
J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):167-74. PubMed ID: 9200531
[TBL] [Abstract][Full Text] [Related]
6. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
[TBL] [Abstract][Full Text] [Related]
7. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
Souid AK; Fahey RC; Aktas MK; Sayin OA; Karjoo S; Newton GL; Sadowitz PD; Dubowy RL; Bernstein ML
Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
[TBL] [Abstract][Full Text] [Related]
8. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a method for measuring the radioprotective metabolite WR-1065 in plasma using chemical derivatization combined with UHPLC-MS/MS.
Simon ES; Reyna D; Lister RJ; Harteg C; Lipka E
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Mar; 1080():82-89. PubMed ID: 29482122
[TBL] [Abstract][Full Text] [Related]
10. Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
Ranganathan K; Simon E; Lynn J; Snider A; Zhang Y; Nelson N; Donneys A; Rodriguez J; Buchman L; Reyna D; Lipka E; Buchman SR
Pharm Res; 2018 Mar; 35(5):99. PubMed ID: 29556791
[TBL] [Abstract][Full Text] [Related]
11. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy.
Feng M; Smith DE; Normolle DP; Knol JA; Pan CC; Ben-Josef E; Lu Z; Feng MR; Chen J; Ensminger W; Lawrence TS
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1441-7. PubMed ID: 22440042
[TBL] [Abstract][Full Text] [Related]
13. Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography.
Souid AK; Newton GL; Dubowy RL; Fahey RC; Bernstein ML
Cancer Chemother Pharmacol; 1998; 42(5):400-6. PubMed ID: 9771955
[TBL] [Abstract][Full Text] [Related]
14. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
[TBL] [Abstract][Full Text] [Related]
15. Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid chromatography.
Bonner HS; Shaw LM
J Chromatogr B Biomed Sci Appl; 2000 Mar; 739(2):357-62. PubMed ID: 10755379
[TBL] [Abstract][Full Text] [Related]
16. Human pharmacokinetics of WR-2721.
Shaw LM; Turrisi AT; Glover DJ; Bonner HS; Norfleet AL; Weiler C; Kligerman MM
Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1501-4. PubMed ID: 3019968
[TBL] [Abstract][Full Text] [Related]
17. New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
Bonner HS; Shaw LM
J Clin Pharmacol; 2002 Feb; 42(2):166-74. PubMed ID: 11831539
[TBL] [Abstract][Full Text] [Related]
18. In vitro metabolism of the phosphorothioate radioprotectors WR-2721 and WR-3689.
Livesey JC; Rasey JS; Vertrees S; Freeman LM; Magee S; Nelson NJ; Chin L; Grunbaum Z; Krohn KA
Pharmacol Ther; 1988; 39(1-3):215-7. PubMed ID: 2849127
[No Abstract] [Full Text] [Related]
19. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Fouladi M; Stempak D; Gammon J; Klein J; Grant R; Greenberg ML; Koren G; Baruchel S
Cancer; 2001 Aug; 92(4):914-23. PubMed ID: 11550166
[TBL] [Abstract][Full Text] [Related]
20. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
Shaw LM; Bonner HS; Brown DQ
Drug Metab Dispos; 1994; 22(6):895-902. PubMed ID: 7895607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
